Skip to main content
Premium Trial:

Request an Annual Quote

Biacore s Q4 Revenue Rose 23 Percent on US Sales Recovery

This article has been updated from a previous version to include Biacore's R&D spending and cash assets.

 

NEW YORK, Feb. 23 (GenomeWeb News) - Biacore today said that sales for the fourth quarter rose 23 percent to 193.7 million Swedish kronor ($24.6 million) from 157.1 million Swedish kronor a year ago.

 

Sales in the US rose 48 percent and European sales were up 45 percent, but receipts in Asia-Pacific declined by 20 percent.

 

Biacore posted fourth-quarter net income of 49.4 million Swedish kronor, or 5.06 Swedish kronor per share, versus 24.4 million Swedish kronor, or 2.51 Swedish kronor per share, during the same period last year.

 

R&D spending rose to 27.0 million Swedish kronor from 23.2 million Swedish kronor in the fourth quarter of 2004.

 

The company said it expects 2006 sales to increase "at approximately the same rate as in 2005 with modest growth in the first quarter."

 

As of Dec. 31, the company had 157.9 million Swedish kronor in cash and cash equivalents.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.